[Current status and future of drug therapy for advanced gastroenteropancreatic neuroendocrine tumors].

Authors

Yihebali Chi, H K Wang

Published in

Zhonghua yi xue za zhi. Volume 106. Issue 31. Pages 3205-3213. Aug 25, 2026.

Abstract

The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NET) has been on the rise, and the treatment strategies for advanced cases have become increasingly diverse. This article aims to explore the evolution of the drug treatment landscape for advanced GEP-NET, systematically reviewing the evidence-based medical progress of core approaches such as somatostatin analogues, targeted therapy, chemotherapy, immunotherapy, and peptide receptor radionuclide therapy. On this basis, it focuses on analyzing challenges currently faced in clinical decision-making, such as optimizing treatment sequences, overcoming drug resistance mechanisms, and developing biomarkers. Expert opinions and prospects based on clinical practice were proposed regarding future directions such as drug combination strategies, exploration of novel therapies, and precision treatment models to explore the current status and future of advanced GEP-NET drug therapy.

PMID:
42618497
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.